Capecitabine for locally advanced and metastatic colorectal cancer: A review

Table 1 Randomized controlled trials comparing capecitabine with standard 5-fluorouracil/leucovorin in patients with metastatic colorectal cancer

Author	Treatment arms	OS (mo)	RR (%)	PFS (mo)	FFS (mo)	Major toxicity
Hoff et al[12]	ARM1: LV 20 mg/m2 iv + 5-FU 425 mg/m2/per day iv, days 1-5 every 4 wk	13.3	11.6	4.7	3.1	More stomatitis with 5-FU/LV (16% vs 3%)
	ARM2: Capecitabine 2500 mg/m2 per day, for 14 d every 21 d per os	12.5	25.8 (P = 0.005)	4.3	4.1	More hand-foot syndrome with capecitabine (18% vs 1%)
Van Cutsem et al[13]	ARM1: LV 20 mg/m2 iv + 5-FU 425 mg/m2 per day iv, days 1-5 every 4 wk	12.1	15	4.7	4.0	More stomatitis with 5-FU/LV (13.3% vs 1.3%)
	ARM2: Capecitabine 2500 mg/m2per day, for 14 d every 21 d per os	13.2	18.9	5.2	4.2	More hand-foot syndrome with capecitabine (16.2% vs 0.3%)

OS: Overall survival; RR: Response rate; PFS: Progression-free survival; FFS: Failure-free survival; LV: Leucovorin; 5-FU: 5-fluorouracil.